Annogen
Startup
Orphan drug developers need safe and effective advanced therapies with minimal off-target effects. Annogen offers validated, bespoke gene promoters —the genetic switches and genomic sites—to achieve highly specific gene expression in the right tissues and right conditions.
Our proprietary SuRE™ and AIM™ technologies are leveraged for controlled therapeutic gene expression in gene and cell therapies. This engineering ensures improved safety and effectiveness by identifying optimal regulatory DNA elements and favorable gene insertion sites from over 100,000 integrations. We offer both tailored de novo screens and off-the-shelf promoters readily available for licensing, e.g. for microglia, T-cells, skeletal muscle, cardiac, neuro-inflammation and ubiquitous applications.
As the trusted partner for bespoke gene expression to dozens of leading biopharma, Annogen helps orphan drug developers optimize their strategies by enabling precise and targeted therapeutic gene (over-)expression.
Annogen was founded in 2017 from the world-renowned Netherlands Cancer Institute (NKI). Today, Annogen is the trusted partner for bespoke gene expression engineering for leading biopharmaceutical, agricultural and academic research centers globally.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events